Oliver Freudenreich, MD
Psychosis Clinical and Research Program, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
Original Research
Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
October 13, 2025
This pilot trial suggests that brexpiprazole might be beneficial in reducing substance craving and use and improve quality of life in this difficult-to-treat patient population.
Case Report
Comprehensive Evaluation Detects Seizure Disorder That Exacerbated Catatonia and Treatment-Resistant Schizophrenia
December 22, 2022
In this young man, continuous video-EEG monitoring revealed undiagnosed seizures that, once treated, helped resolve his catatonia and reduce symptoms of schizophrenia.
Brief Report
Long-Acting Injectable Antipsychotic Management During COVID-19
January 12, 2021
Long-acting injectable antipsychotics are effective for preventing relapse in schizophrenia, but in-person administration of them is a challenge during a pandemic. This report describes how a clinic successfully reduced...
Letter to the Editor
Lamotrigine Cross-Reactivity With Phencyclidine in a Research Study
July 26, 2018
Routine urine drug screening in research trials is an underappreciated risk for trial participants. Here, the authors present a case of lamotrigine cross-reactivity with phencyclidine in a clinical trial...
